atenolol has been researched along with Body Weight in 74 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We investigated whether body build was independently associated with higher cardiovascular risk and whether treatment with losartan relative to atenolol influenced the impact of body build on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and on cardiovascular death in patients with hypertension and left ventricular hypertrophy in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 9.11 | Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. ( Beevers, G; Dahlöf, B; de Faire, U; de Simone, G; Devereux, RB; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Palmieri, V; Wachtell, K, 2005) |
| "The effects on glucose metabolism by the beta-blocker atenolol and the angiotensin-converting enzyme (ACE)-inhibitor trandolapril were investigated in a randomised double-blind parallel group study of patients with primary hypertension." | 9.09 | Induction of insulin resistance by beta-blockade but not ACE-inhibition: long-term treatment with atenolol or trandolapril. ( Alvarez, E; Andersson, PE; Byberg, L; Haenni, A; Lithell, H; Reneland, R, 2000) |
| "Forty-nine patients, with ages ranging from eighteen to seventy years and with mild to moderate primary hypertension (sitting diastolic blood pressure of greater than or equal to 95 mmgH and less than or equal to 115 mmHg) were randomized into a twenty-one-week, double-blind, prospective study to determine the effects of monotherapy of nifedipine GITS (gastrointestinal therapeutic system) versus atenolol on serum lipids, lipid subfractions, apolipoproteins, (apo), and blood pressure (BP)." | 9.07 | Effects of nifedipine GITS and atenolol monotherapy on serum lipids, blood pressure, heart rate, and weight in mild to moderate hypertension. ( Burger, MC; Houston, MC; Olafsson, L, 1991) |
| "We describe the results of a prospective study in which 120 women who developed hypertension in the last trimester of pregnancy were randomly allocated in double blind manner to atenolol or placebo." | 9.05 | First year of life after the use of atenolol in pregnancy associated hypertension. ( Adams, T; Butters, L; Evans, J; Reynolds, B; Rubin, PC, 1984) |
| "The effectiveness and tolerability of nitrendipine (Bay e 5009) and atenolol in the treatment of mild or moderate arterial hypertension in monotherapy and in association were evaluated in a randomized double-blind study." | 9.05 | Nitrendipine and atenolol: comparison and combination in the treatment of arterial hypertension. ( de Divitiis, O; Di Somma, S; Fazio, S; Galderisi, M; Petitto, M; Santomauro, M; Villari, B, 1985) |
| "Because of the difficulties patients have in adhering to their drug regimens a trial was performed in which patients with essential hypertension were given, in random order and for four weeks each, three different doses of atenolol to be taken once daily." | 9.04 | Once-daily dosing with Atenolol in patients with mild or moderate hypertension. ( Cruickshank, JM; Douglas-Jones, AP, 1976) |
| "The stimulus for carbon monoxide-induced cardiac hypertrophy was investigated." | 7.68 | Carbon monoxide-induced cardiac hypertrophy is not reduced by alpha- or beta-blockade in the rat. ( Formolo, JM; Penney, DG, 1993) |
| "In this study the clinical, biological, radiologic, electrocardiographic, and hormonal characteristics of 80 patients with slight or moderate essential arterial hypertension in whom the treatment with atenolol alone or associated with chlorthalidone or with a third agent normalized the arterial pressure during a period of one year, are revised." | 7.68 | [The clinical profile of hypertensive patients can predict the need for combining a second or third drug with atenolol in the initial treatment of light and moderate essential arterial hypertension]. ( Aguilera, MT; Coca, A; de la Sierra, A; Lluch, MM; Picado, MJ; Sánchez, M; Sobrino, J; Urbano-Márquez, A, 1990) |
| "To investigate the involvement of adrenergic mechanisms in the development of obesity, hyperglycaemia and hyperinsulinaemia in Aston ob/ob mice, the sympathomimetic agent ephedrine (12 mg/kg/day) and the predominantly beta 1-adrenergic antagonist atenolol (12 mg/kg/day) were administered alone and in combination to weanling ob/ob mice for 40 days." | 7.67 | Effects of ephedrine and atenolol on the development of obesity and diabetes in ob/ob mice. ( Bailey, CJ; Flatt, PR; Thornburn, CC, 1986) |
| "A 22 year old woman presented with lupus nephritis, hypertension, and intractable nephrotic syndrome." | 5.28 | Antiproteinuric effect of captopril in a patient with lupus nephritis and intractable nephrotic syndrome. ( Friedler, A; Mor, F; Shapira, Y; Weinberger, A; Wysenbeek, AJ, 1990) |
| "Treatment with atenolol markedly inhibited the onset of genetic hypertension, reduced HR and PRC from the outset and diminished the heart weight/body weight ratio." | 5.26 | Chronic atenolol treatment and hypertension development in spontaneously hypertensive rats. ( Boissier, JR; Giudicelli, JF; Richer, C, 1978) |
| " We investigated whether body build was independently associated with higher cardiovascular risk and whether treatment with losartan relative to atenolol influenced the impact of body build on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and on cardiovascular death in patients with hypertension and left ventricular hypertrophy in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 5.11 | Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. ( Beevers, G; Dahlöf, B; de Faire, U; de Simone, G; Devereux, RB; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Palmieri, V; Wachtell, K, 2005) |
| "The effects on glucose metabolism by the beta-blocker atenolol and the angiotensin-converting enzyme (ACE)-inhibitor trandolapril were investigated in a randomised double-blind parallel group study of patients with primary hypertension." | 5.09 | Induction of insulin resistance by beta-blockade but not ACE-inhibition: long-term treatment with atenolol or trandolapril. ( Alvarez, E; Andersson, PE; Byberg, L; Haenni, A; Lithell, H; Reneland, R, 2000) |
| "Forty-nine patients, with ages ranging from eighteen to seventy years and with mild to moderate primary hypertension (sitting diastolic blood pressure of greater than or equal to 95 mmgH and less than or equal to 115 mmHg) were randomized into a twenty-one-week, double-blind, prospective study to determine the effects of monotherapy of nifedipine GITS (gastrointestinal therapeutic system) versus atenolol on serum lipids, lipid subfractions, apolipoproteins, (apo), and blood pressure (BP)." | 5.07 | Effects of nifedipine GITS and atenolol monotherapy on serum lipids, blood pressure, heart rate, and weight in mild to moderate hypertension. ( Burger, MC; Houston, MC; Olafsson, L, 1991) |
| "Twenty-eight patients with mild to moderate essential hypertension well controlled by atenolol entered a five-week, double-blind, placebo-controlled trial of the effects of sulindac and naproxen on blood pressure (BP) control." | 5.06 | Effect of naproxen and sulindac on blood pressure response to atenolol. ( Abate, MA; D'Alessandri, R; Layne, RD; Neely, JL, 1990) |
| "The effectiveness and tolerability of nitrendipine (Bay e 5009) and atenolol in the treatment of mild or moderate arterial hypertension in monotherapy and in association were evaluated in a randomized double-blind study." | 5.05 | Nitrendipine and atenolol: comparison and combination in the treatment of arterial hypertension. ( de Divitiis, O; Di Somma, S; Fazio, S; Galderisi, M; Petitto, M; Santomauro, M; Villari, B, 1985) |
| "We describe the results of a prospective study in which 120 women who developed hypertension in the last trimester of pregnancy were randomly allocated in double blind manner to atenolol or placebo." | 5.05 | First year of life after the use of atenolol in pregnancy associated hypertension. ( Adams, T; Butters, L; Evans, J; Reynolds, B; Rubin, PC, 1984) |
| "Because of the difficulties patients have in adhering to their drug regimens a trial was performed in which patients with essential hypertension were given, in random order and for four weeks each, three different doses of atenolol to be taken once daily." | 5.04 | Once-daily dosing with Atenolol in patients with mild or moderate hypertension. ( Cruickshank, JM; Douglas-Jones, AP, 1976) |
| "Blockade of the renin-angiotensin system but not antihypertensive therapy with atenolol reduces vascular pathology in diabetic Ren-2 retina, suggesting that angiotensin II is a causative factor and therapeutic target in diabetic retinopathy." | 3.74 | Valsartan but not atenolol improves vascular pathology in diabetic Ren-2 rat retina. ( Jaworski, K; Ninkovic, S; Tan, G; Wilkinson-Berka, JL, 2007) |
| "To investigate whether chronic selective beta1-blockade with nebivolol could prevent endothelial dysfunction in salt-induced hypertension, and to compare it with atenolol." | 3.71 | Nitric-oxide-mediated relaxations in salt-induced hypertension: effect of chronic beta1 -selective receptor blockade. ( Bonetti, S; Cosentino, F; Eto, M; Lüscher, TF; Rehorik, R; Volpe, M; Werner-Felmayer, G, 2002) |
| "The effects of propranolol and atenolol were investigated on arterial hypertension, cardiomyocyte hypertrophy, and ventricular ischaemic lesions induced by an 8-week treatment with the nitric oxide synthase inhibitor N(omega)-nitro-L-arginine methyl ester (L-NAME; 20 mg/rat per day) in Wistar rats." | 3.71 | Attenuation of hypertension, cardiomyocyte hypertrophy, and myocardial fibrosis by beta-adrenoceptor blockers in rats under long-term blockade of nitric oxide synthesis. ( Antunes, E; de Azevedo, AP; De Luca, IM; De Nucci, G; De Oliveira, CF; Pacca, SR, 2002) |
| "To determine whether beta blockade protects against the acceleration of lipid peroxidation in hyperthyroid rat soleus (slow-oxidative) muscle, in vivo chronic (3 weeks) effects of 3 beta blockers with different ancillary properties on mitochondrial oxidative enzymes, antioxidant enzymes, and thiobarbituric acid-reactive substances were investigated." | 3.68 | Differential effects of 3 beta blockers on lipid peroxidation in hyperthyroid muscle. ( Asayama, K; Dobashi, K; Hayashibe, H; Kato, K, 1990) |
| "Increased motor activity and poor performance in the active avoidance test were observed in the offspring of rats treated with dl-propranolol or sotalol during pregnancy, but not with atenolol and d-propranolol." | 3.68 | Behavioral and biochemical studies in rats following prenatal treatment with beta-adrenoceptor antagonists. ( Gitter, S; Gordon, I; Rehavi, M; Speiser, Z, 1991) |
| "The stimulus for carbon monoxide-induced cardiac hypertrophy was investigated." | 3.68 | Carbon monoxide-induced cardiac hypertrophy is not reduced by alpha- or beta-blockade in the rat. ( Formolo, JM; Penney, DG, 1993) |
| "In this study the clinical, biological, radiologic, electrocardiographic, and hormonal characteristics of 80 patients with slight or moderate essential arterial hypertension in whom the treatment with atenolol alone or associated with chlorthalidone or with a third agent normalized the arterial pressure during a period of one year, are revised." | 3.68 | [The clinical profile of hypertensive patients can predict the need for combining a second or third drug with atenolol in the initial treatment of light and moderate essential arterial hypertension]. ( Aguilera, MT; Coca, A; de la Sierra, A; Lluch, MM; Picado, MJ; Sánchez, M; Sobrino, J; Urbano-Márquez, A, 1990) |
| "In patients with mild hypertension, flurbiprofen in a dose of 100 mg daily for 7 days attenuated the hypotensive effect of a single dose of propranolol 80 mg but not of atenolol 100 mg." | 3.67 | Flurbiprofen interaction with single doses of atenolol and propranolol. ( Hawksworth, GM; McLean, I; Petrie, JC; Webster, J, 1984) |
| "To investigate the involvement of adrenergic mechanisms in the development of obesity, hyperglycaemia and hyperinsulinaemia in Aston ob/ob mice, the sympathomimetic agent ephedrine (12 mg/kg/day) and the predominantly beta 1-adrenergic antagonist atenolol (12 mg/kg/day) were administered alone and in combination to weanling ob/ob mice for 40 days." | 3.67 | Effects of ephedrine and atenolol on the development of obesity and diabetes in ob/ob mice. ( Bailey, CJ; Flatt, PR; Thornburn, CC, 1986) |
| "The effects of propranolol (100 mg/kg), atenolol (200 mg/kg) and acebutolol (1000 mg/kg) administered daily by gavage to spontaneously hypertensive rats (SHRs) from their 6th to 20th weeks of age were investigated on genetic hypertension development (GHD) and at regular intervals on heart rate (HR), cardiac output (CO), stroke volume (SV), peripheral resistence (PR), plasma renin concentration (PRC) and heart weight/body weight ratio (HW/BW)." | 3.66 | beta-Adrenoreceptor blockage and genetic hypertension development in rats. ( Boissier, JR; Giudicelli, JF; Richer, C; Venturini-Souto, N, 1980) |
| "In long-term hemodialysis patients, treating hypertension using home BP measurements may improve well-being." | 2.82 | Treating hypertension in hemodialysis improves symptoms seemingly unrelated to volume excess. ( Agarwal, R, 2016) |
| "Most individuals with type 2 diabetes are affected by hypertension and thus have higher risk of cardiac complications." | 2.73 | Impact of beta-blocker treatment and nutritional status on glycemic response during exercise in patients with type 2 diabetes. ( Bergeron, J; Brassard, P; Croteau, S; Ferland, A; Fournier, L; Lacroix, S; Lemieux, S; Poirier, P, 2007) |
| " Pharmacokinetic parameters of atenolol were calculated using a one-compartment open model." | 2.71 | Effect of unilateral nephrectomy on the pharmacokinetics of atenolol in humans. ( Domanski, L; Drozdzik, M; Machoy, P; Pudlo, A; Wojcicki, J, 2003) |
| "In hypertensive patients with chronic renal failure enalapril slows progression towards end stage renal failure compared with beta blockers." | 2.67 | Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. ( Chanard, J; Durand, D; el Esper, N; Fournier, A; Godin, M; Goldfarb, B; Hannedouche, T; Landais, P; Mignon, F; Suo, JM, 1994) |
| "Atenolol did not cause any significant change in the total cholesterol but increased HDL cholesterol by 7% at 1 month, the change being due to rise of the HDL3." | 2.66 | Lipoprotein lipids and apoproteins during beta-blocker administration: comparison of penbutolol and atenolol. ( Harno, K; Maass, L; Nikkilä, EA; Välimäki, M, 1986) |
| " Mice were phenotyped either in response to chronic administration of a single dose of the beta-adrenergic receptor blocker atenolol or under a low and a high dose of the beta-agonist isoproterenol and compared to baseline condition." | 1.35 | Cardiovascular response to beta-adrenergic blockade or activation in 23 inbred mouse strains. ( Abriel, H; Beckmann, JS; Bergmann, S; Berthonneche, C; Hayoz, P; Kutalik, Z; Maurer, F; Pedrazzini, T; Peter, B; Schüpfer, F, 2009) |
| " We characterized the effect of cardiac sympathetic denervation on basal levels of mean arterial pressure (MAP) and heart rate (HR) and the responses to a chronic administration of atenolol, a beta1-adrenoceptor antagonist." | 1.35 | Effect of stellate ganglionectomy on basal cardiovascular function and responses to beta1-adrenoceptor blockade in the rat. ( Kreulen, DL; Novotny, M; Osborn, JW; Swain, GM; Wehrwein, EA; Yoshimoto, M, 2008) |
| "Atenolol is a beta-adrenergic receptor antagonist ('beta-blocker') widely used for the treatment of angina, glaucoma, high blood pressure and other related conditions." | 1.35 | Defining the chronic impacts of atenolol on embryo-larval development and reproduction in the fathead minnow (Pimephales promelas). ( Alder, AC; Caunter, JE; Giltrow, E; Hutchinson, TH; Lillicrap, AD; Ramil, M; Schaffner, C; Sumpter, JP; Ternes, TA; Winter, MJ, 2008) |
| "Lycopus extract was tested in thyroxine treated hyperthyroid rats (0." | 1.33 | Extract of Lycopus europaeus L. reduces cardiac signs of hyperthyroidism in rats. ( Baumgartner, A; Biller, A; Hegger, M; Korte, B; Vonhoff, C; Winterhoff, H, 2006) |
| "Atenolol treatment prevented the increase in both protein expression (low sodium plus atenolol, 27." | 1.31 | Cardiac betaARK1 upregulation induced by chronic salt deprivation in rats. ( Barbato, E; Cipolleta, E; Esposito, A; Fiorillo, A; Iaccarino, G; Koch, WJ; Trimarco, B, 2001) |
| "Propranolol is a lipophilic non-selective beta-blocker mainly eliminated via the liver; atenolol is a hydrophilic beta 1-selective blocking agent, mainly eliminated via the kidney." | 1.29 | Evaluation of the tumor-promoting activity of two beta-adrenoreceptor blocking agents, propranolol and atenolol, in liver of Fischer 344 rats. ( Ameri, L; Arias, E; Girotti, P; Mazzoleni, G; Presta, M; Radaelli, G; Ragnotti, G; Zavanella, T, 1994) |
| "A 22 year old woman presented with lupus nephritis, hypertension, and intractable nephrotic syndrome." | 1.28 | Antiproteinuric effect of captopril in a patient with lupus nephritis and intractable nephrotic syndrome. ( Friedler, A; Mor, F; Shapira, Y; Weinberger, A; Wysenbeek, AJ, 1990) |
| "Indomethacin and sulindac were used as tools to study the role of renal and/or systemic prostaglandins in the pharmacological response to atenolol." | 1.27 | The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients. ( Abdel-Haq, B; Alberici, P; Magagna, A; Pedrinelli, R; Salvetti, A, 1984) |
| "Atenolol failed to produce significant systemic toxic effects not only on weight gains and daily intakes of food but also on death rates." | 1.27 | Role of endogenous beta-adrenergic mechanism in the pathogenesis of spontaneous myocardial fibrosis in rats. ( Hashimoto, K; Yoshimura, S, 1988) |
| "Atenolol was injected subcutaneously (20 mg/kg) twice daily commencing in four-week-old rats." | 1.27 | The effects of beta adrenoceptor blockade with atenolol on myocardial cellular and subcellular hypertrophy in spontaneously hypertensive rats. ( Lauva, IK; Tomanek, RJ, 1983) |
| "Atenolol did not lower the Km value, but reduced significantly the Vmax value of the 10 weeks treated heart MAO." | 1.27 | [Effect of atenolol on MAO activities in SHR]. ( Nakayama, S; Ohba, T; Sakamoto, K; Tsuji, T, 1986) |
| "Treatment with atenolol markedly inhibited the onset of genetic hypertension, reduced HR and PRC from the outset and diminished the heart weight/body weight ratio." | 1.26 | Chronic atenolol treatment and hypertension development in spontaneously hypertensive rats. ( Boissier, JR; Giudicelli, JF; Richer, C, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 30 (40.54) | 18.7374 |
| 1990's | 21 (28.38) | 18.2507 |
| 2000's | 17 (22.97) | 29.6817 |
| 2010's | 6 (8.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ramos-Filho, AC | 1 |
| Moscoso, JA | 1 |
| Calmasini, F | 1 |
| Faria, Jde A | 1 |
| Anhê, GF | 1 |
| Mónica, FZ | 1 |
| Antunes, E | 2 |
| Agarwal, R | 1 |
| Mani, BK | 1 |
| Osborne-Lawrence, S | 1 |
| Vijayaraghavan, P | 1 |
| Hepler, C | 1 |
| Zigman, JM | 1 |
| Damian, DJ | 1 |
| McNamee, R | 1 |
| Carr, M | 1 |
| Yoshimoto, M | 1 |
| Wehrwein, EA | 1 |
| Novotny, M | 1 |
| Swain, GM | 1 |
| Kreulen, DL | 1 |
| Osborn, JW | 1 |
| Ara, N | 1 |
| Rashid, M | 1 |
| Amran, MS | 1 |
| Berthonneche, C | 1 |
| Peter, B | 1 |
| Schüpfer, F | 1 |
| Hayoz, P | 1 |
| Kutalik, Z | 1 |
| Abriel, H | 1 |
| Pedrazzini, T | 1 |
| Beckmann, JS | 1 |
| Bergmann, S | 1 |
| Maurer, F | 1 |
| Trinity, JD | 1 |
| Pahnke, MD | 1 |
| Lee, JF | 1 |
| Coyle, EF | 1 |
| Mabe, AM | 1 |
| Hoover, DB | 1 |
| Drozdzik, M | 1 |
| Domanski, L | 1 |
| Wojcicki, J | 1 |
| Pudlo, A | 1 |
| Machoy, P | 1 |
| Minami, N | 1 |
| Yoshikawa, T | 1 |
| Kataoka, H | 1 |
| Mori, N | 1 |
| Nagasaka, M | 1 |
| Kurosawa, H | 1 |
| Kanazawa, M | 1 |
| Kohzuki, M | 1 |
| van Brakel, TJ | 1 |
| Hermans, JJ | 1 |
| Janssen, BJ | 1 |
| van Essen, H | 1 |
| Botterhuis, N | 1 |
| Smits, JF | 1 |
| Maessen, JG | 1 |
| de Simone, G | 1 |
| Wachtell, K | 1 |
| Palmieri, V | 1 |
| Hille, DA | 1 |
| Beevers, G | 1 |
| Dahlöf, B | 1 |
| de Faire, U | 1 |
| Fyhrquist, F | 1 |
| Ibsen, H | 1 |
| Julius, S | 1 |
| Kjeldsen, SE | 3 |
| Lederballe-Pedersen, O | 1 |
| Lindholm, LH | 1 |
| Nieminen, MS | 1 |
| Omvik, P | 1 |
| Oparil, S | 1 |
| Devereux, RB | 1 |
| Vonhoff, C | 1 |
| Baumgartner, A | 1 |
| Hegger, M | 1 |
| Korte, B | 1 |
| Biller, A | 1 |
| Winterhoff, H | 1 |
| Wilkinson-Berka, JL | 1 |
| Tan, G | 1 |
| Jaworski, K | 1 |
| Ninkovic, S | 1 |
| Grippo, AJ | 1 |
| Lamb, DG | 1 |
| Carter, CS | 1 |
| Porges, SW | 1 |
| Ferland, A | 1 |
| Brassard, P | 1 |
| Croteau, S | 1 |
| Lemieux, S | 1 |
| Bergeron, J | 1 |
| Lacroix, S | 1 |
| Fournier, L | 1 |
| Poirier, P | 1 |
| Winter, MJ | 1 |
| Lillicrap, AD | 1 |
| Caunter, JE | 1 |
| Schaffner, C | 1 |
| Alder, AC | 1 |
| Ramil, M | 1 |
| Ternes, TA | 1 |
| Giltrow, E | 1 |
| Sumpter, JP | 1 |
| Hutchinson, TH | 1 |
| Lauva, IK | 1 |
| Tomanek, RJ | 1 |
| Mills, PR | 1 |
| Rae, AP | 1 |
| Farah, DA | 1 |
| Russell, RI | 1 |
| Lorimer, AR | 1 |
| Carter, DC | 1 |
| Skjøtø, J | 2 |
| Aakesson, I | 2 |
| Os, I | 2 |
| Eide, I | 1 |
| Leren, P | 2 |
| Salvetti, A | 1 |
| Pedrinelli, R | 1 |
| Alberici, P | 1 |
| Magagna, A | 1 |
| Abdel-Haq, B | 1 |
| Reynolds, B | 1 |
| Butters, L | 1 |
| Evans, J | 1 |
| Adams, T | 1 |
| Rubin, PC | 1 |
| Webster, J | 2 |
| Petrie, JC | 2 |
| McLean, I | 1 |
| Hawksworth, GM | 1 |
| Sau, F | 1 |
| Seguro, C | 1 |
| Pisano, MR | 1 |
| Pirisi, R | 1 |
| Raffo, M | 1 |
| Cherchi, A | 1 |
| Richer, C | 2 |
| Venturini-Souto, N | 1 |
| Boissier, JR | 2 |
| Giudicelli, JF | 2 |
| Anania, V | 1 |
| Bartoli, E | 1 |
| Desole, MS | 1 |
| Faedda, R | 1 |
| Miele, E | 1 |
| Olmeo, NA | 1 |
| Satta, A | 1 |
| Soggia, G | 1 |
| Vacca, R | 1 |
| Kähönen, M | 1 |
| Mäkynen, H | 1 |
| Arvola, P | 1 |
| Pörsti, I | 1 |
| Hannedouche, T | 1 |
| Landais, P | 1 |
| Goldfarb, B | 1 |
| el Esper, N | 1 |
| Fournier, A | 1 |
| Godin, M | 1 |
| Durand, D | 1 |
| Chanard, J | 1 |
| Mignon, F | 1 |
| Suo, JM | 1 |
| Zavanella, T | 2 |
| Radaelli, G | 2 |
| Girotti, P | 1 |
| Arias, E | 1 |
| Ameri, L | 1 |
| Presta, M | 1 |
| Mazzoleni, G | 1 |
| Ragnotti, G | 2 |
| Penney, DG | 1 |
| Formolo, JM | 1 |
| Wylie-Rosett, J | 1 |
| Wassertheil-Smoller, S | 2 |
| Blaufox, MD | 2 |
| Davis, BR | 1 |
| Langford, HG | 1 |
| Oberman, A | 2 |
| Jennings, S | 1 |
| Hataway, H | 1 |
| Stern, J | 1 |
| Zimbaldi, N | 1 |
| Haneda, T | 1 |
| Okamoto, K | 1 |
| Hiroshima, T | 1 |
| Kashiwagi, Y | 1 |
| Miyata, S | 1 |
| Ohi, S | 1 |
| Nakamura, Y | 1 |
| Osaki, J | 1 |
| Hirayama, T | 1 |
| Ogawa, Y | 1 |
| Crichton, F | 1 |
| Dimmitt, SB | 1 |
| Williams, PD | 1 |
| Croft, KD | 1 |
| Beilin, LJ | 1 |
| Cardani, R | 1 |
| Reneland, R | 1 |
| Alvarez, E | 1 |
| Andersson, PE | 1 |
| Haenni, A | 1 |
| Byberg, L | 1 |
| Lithell, H | 1 |
| Iaccarino, G | 1 |
| Barbato, E | 1 |
| Cipolleta, E | 1 |
| Esposito, A | 1 |
| Fiorillo, A | 1 |
| Koch, WJ | 1 |
| Trimarco, B | 2 |
| Pacca, SR | 1 |
| de Azevedo, AP | 1 |
| De Oliveira, CF | 1 |
| De Luca, IM | 1 |
| De Nucci, G | 1 |
| Cosentino, F | 1 |
| Bonetti, S | 1 |
| Rehorik, R | 1 |
| Eto, M | 1 |
| Werner-Felmayer, G | 1 |
| Volpe, M | 1 |
| Lüscher, TF | 1 |
| Brown, RA | 1 |
| Ilg, KJ | 1 |
| Chen, AF | 1 |
| Ren, J | 1 |
| Reybrouck, T | 1 |
| Amery, A | 1 |
| Billiet, L | 1 |
| Fagard, R | 1 |
| Douglas-Jones, AP | 1 |
| Cruickshank, JM | 1 |
| Galloway, DB | 1 |
| Simpson, WT | 1 |
| Lewis, JA | 1 |
| Speiser, Z | 1 |
| Gordon, I | 1 |
| Rehavi, M | 1 |
| Gitter, S | 1 |
| Asayama, K | 1 |
| Hayashibe, H | 1 |
| Dobashi, K | 1 |
| Kato, K | 1 |
| Davis, B | 1 |
| Langford, H | 1 |
| Jansson, JH | 1 |
| Johansson, B | 1 |
| Boman, K | 1 |
| Nilsson, TK | 1 |
| Houston, MC | 1 |
| Olafsson, L | 1 |
| Burger, MC | 1 |
| Bürgi, U | 2 |
| Bürgi-Saville, ME | 2 |
| Burgherr, J | 1 |
| Clément, M | 1 |
| Lauber, K | 1 |
| Mehvar, R | 1 |
| Shah, PK | 1 |
| Lakhotia, M | 1 |
| Chittora, M | 1 |
| Mehta, S | 2 |
| Vyas, R | 1 |
| Parihar, M | 1 |
| Shapira, Y | 1 |
| Mor, F | 1 |
| Friedler, A | 1 |
| Wysenbeek, AJ | 1 |
| Weinberger, A | 1 |
| Abate, MA | 1 |
| Layne, RD | 1 |
| Neely, JL | 1 |
| D'Alessandri, R | 1 |
| Coca, A | 1 |
| de la Sierra, A | 1 |
| Sobrino, J | 1 |
| Aguilera, MT | 1 |
| Lluch, MM | 1 |
| Sánchez, M | 1 |
| Picado, MJ | 1 |
| Urbano-Márquez, A | 1 |
| Sykulski, R | 1 |
| Keller, N | 1 |
| Storm, T | 1 |
| Stokke, O | 1 |
| Myhre, T | 1 |
| Himanen, P | 1 |
| Quitzau, K | 1 |
| Reams, GP | 1 |
| Bauer, JH | 1 |
| Ziegler, F | 1 |
| Krähenbühl, L | 1 |
| Huber, G | 1 |
| Schoch, C | 1 |
| Nagamine, F | 1 |
| Murakami, K | 1 |
| Mimura, G | 1 |
| Sakanashi, M | 1 |
| Yoshimura, S | 1 |
| Hashimoto, K | 1 |
| Westheim, A | 1 |
| Lande, K | 1 |
| Frederichsen, P | 1 |
| Hjermann, I | 1 |
| Eide, IK | 1 |
| Tucker, DC | 1 |
| Domino, JV | 1 |
| Nafstad, I | 1 |
| Tollersrud, S | 1 |
| Eriksen, K | 1 |
| Helgeland, A | 1 |
| Solberg, LA | 1 |
| Bredesen, J | 1 |
| Dale, O | 1 |
| Lehtonen, A | 1 |
| Ricciardelli, B | 1 |
| De Luca, N | 1 |
| De Simone, A | 1 |
| Cuocolo, A | 1 |
| Galva, MD | 1 |
| Picotti, GB | 1 |
| Condorelli, M | 1 |
| de Divitiis, O | 1 |
| Petitto, M | 1 |
| Di Somma, S | 1 |
| Galderisi, M | 1 |
| Villari, B | 1 |
| Santomauro, M | 1 |
| Fazio, S | 1 |
| Bailey, CJ | 1 |
| Thornburn, CC | 1 |
| Flatt, PR | 1 |
| Välimäki, M | 1 |
| Maass, L | 1 |
| Harno, K | 1 |
| Nikkilä, EA | 1 |
| Costa, FV | 1 |
| Borghi, C | 1 |
| Mussi, A | 1 |
| Ambrosioni, E | 1 |
| Tsuji, T | 1 |
| Ohba, T | 1 |
| Nakayama, S | 1 |
| Sakamoto, K | 1 |
| Koh, H | 1 |
| Nambu, S | 1 |
| Ikeda, M | 1 |
| Ravid, M | 1 |
| Lang, R | 1 |
| Jutrin, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| [NCT00000513] | Phase 3 | 0 participants | Interventional | 1984-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
27 trials available for atenolol and Body Weight
| Article | Year |
|---|---|
Treating hypertension in hemodialysis improves symptoms seemingly unrelated to volume excess.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Blood Volume; Body Weight; Female; Humans; Hypert | 2016 |
Changes in selected metabolic parameters in patients over 65 receiving hydrochlorothiazide plus amiloride, atenolol or placebo in the MRC elderly trial.
Topics: Adrenergic beta-1 Receptor Antagonists; Age Factors; Aged; Amiloride; Antihypertensive Agents; Ateno | 2016 |
Interaction of hyperthermia and heart rate on stroke volume during prolonged exercise.
Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Adult; Atenolol; Bicycling; Blood Volume; Body T | 2010 |
Effect of unilateral nephrectomy on the pharmacokinetics of atenolol in humans.
Topics: Adrenergic beta-Antagonists; Adult; Aging; Area Under Curve; Atenolol; Body Weight; Female; Half-Lif | 2003 |
Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study.
Topics: Aged; Atenolol; Body Mass Index; Body Weight; Cardiovascular Diseases; Female; Humans; Hypertension; | 2005 |
Impact of beta-blocker treatment and nutritional status on glycemic response during exercise in patients with type 2 diabetes.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; | 2007 |
Comparison of three adrenoreceptor blocking agents in patients with cirrhosis and portal hypertension.
Topics: Atenolol; Blood Pressure; Body Weight; Clinical Trials as Topic; Female; Heart Rate; Humans; Hyperte | 1984 |
Increased plasma vasopressin and serum uric acid in the low renin type of essential hypertension.
Topics: Atenolol; Blood Pressure; Body Weight; Catecholamines; Heart Rate; Humans; Hypertension; Male; Middl | 1984 |
First year of life after the use of atenolol in pregnancy associated hypertension.
Topics: Atenolol; Body Height; Body Weight; Clinical Trials as Topic; Double-Blind Method; Female; Humans; H | 1984 |
Hypertension in Diabetes Study. III. Prospective study of therapy of hypertension in type 2 diabetic patients: efficacy of ACE inhibition and beta-blockade.
Topics: Adult; Aged; Atenolol; Blood Glucose; Blood Pressure; Body Weight; Captopril; Cholesterol; Diabetes | 1994 |
Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure.
Topics: Acebutolol; Adolescent; Adult; Aged; Atenolol; Blood Pressure; Body Weight; Enalapril; Female; Human | 1994 |
Trial of antihypertensive intervention and management: greater efficacy with weight reduction than with a sodium-potassium intervention.
Topics: Adult; Analysis of Variance; Atenolol; Blood Pressure; Body Weight; Chlorthalidone; Combined Modalit | 1993 |
Effects of beta-blockers on the concentration and oxidizability of plasma lipids.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood Pressure; Body Weight; Cholesterol, HDL; C | 1998 |
Induction of insulin resistance by beta-blockade but not ACE-inhibition: long-term treatment with atenolol or trandolapril.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Pressur | 2000 |
Once-daily dosing with Atenolol in patients with mild or moderate hypertension.
Topics: Adult; Atenolol; Blood Pressure; Body Weight; Clinical Trials as Topic; Female; Heart Rate; Humans; | 1976 |
Atenolol and bendrofluazide in hypertension.
Topics: Adult; Aged; Atenolol; Bendroflumethiazide; Body Weight; Clinical Trials as Topic; Drug Evaluation; | 1975 |
The Trial of Antihypertensive Interventions and Management (TAIM) Study. Final results with regard to blood pressure, cardiovascular risk, and quality of life.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Body Weight; Cardiovascular Diseases | 1992 |
Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Body Weight; Double-Blind Method; Doxazosi | 1991 |
Effects of nifedipine GITS and atenolol monotherapy on serum lipids, blood pressure, heart rate, and weight in mild to moderate hypertension.
Topics: Adult; Aged; Atenolol; Blood Pressure; Body Weight; Delayed-Action Preparations; Double-Blind Method | 1991 |
Cardiovascular response to dynamic treadmill exercise in patients with essential hypertension before and after therapy with atenolol or captopril.
Topics: Adult; Atenolol; Blood Pressure; Body Weight; Captopril; Exercise Test; Female; Hemodynamics; Humans | 1990 |
Effect of naproxen and sulindac on blood pressure response to atenolol.
Topics: Adult; Aged; Atenolol; Blood Pressure; Body Weight; Double-Blind Method; Drug Interactions; Female; | 1990 |
Double-blind comparison of tiapamil and atenolol in patients with mild to moderate hypertension: a multicenter trial.
Topics: Adult; Aged; Atenolol; Blood Pressure; Body Weight; Calcium Channel Blockers; Double-Blind Method; E | 1989 |
Comparison of the metabolic effects of long-term treatment with pindolol or atenolol by hypertensive patients.
Topics: Adult; Atenolol; Blood Glucose; Body Weight; Cholesterol, LDL; Cholesterol, VLDL; Drug Administratio | 1988 |
Nitrendipine and atenolol: comparison and combination in the treatment of arterial hypertension.
Topics: Adult; Atenolol; Blood Pressure; Body Weight; Calcium Channel Blockers; Clinical Trials as Topic; Do | 1985 |
Lipoprotein lipids and apoproteins during beta-blocker administration: comparison of penbutolol and atenolol.
Topics: Adult; Apoproteins; Atenolol; Blood Pressure; Body Weight; Cholesterol, HDL; Heart Rate; Humans; Hyp | 1986 |
Cadralazine and chlorthalidone as a second-step drug with atenolol in hypertensive patients: differences in blood pressure control during exercise.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Chemical Analysis; Blood Pressure; Body Weight; Chlo | 1986 |
The relative antihypertensive potency of propranolol, oxprenolol, atenolol, and metoprolol given once daily. A double-blind, crossover, placebo-controlled study in ambulatory patients.
Topics: Adult; Aged; Analysis of Variance; Atenolol; Blood Pressure; Body Weight; Delayed-Action Preparation | 1985 |
47 other studies available for atenolol and Body Weight
| Article | Year |
|---|---|
Blockade of renin-angiotensin system prevents micturition dysfunction in renovascular hypertensive rats.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Animals; Antihypertensive Agents; Atenolol; Blood Press | 2014 |
β1-Adrenergic receptor deficiency in ghrelin-expressing cells causes hypoglycemia in susceptible individuals.
Topics: Animals; Atenolol; Blood Glucose; Body Weight; Caloric Restriction; Female; Gastric Mucosa; Gene Del | 2016 |
Effect of stellate ganglionectomy on basal cardiovascular function and responses to beta1-adrenoceptor blockade in the rat.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Atenolol; Blood Pressu | 2008 |
Comparison of hypotensive and hypolipidemic effects of Catharanthus roseus leaves extract with atenolol on adrenaline induced hypertensive rats.
Topics: Animals; Antihypertensive Agents; Atenolol; Blood Glucose; Blood Pressure; Body Weight; Catharanthus | 2009 |
Cardiovascular response to beta-adrenergic blockade or activation in 23 inbred mouse strains.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Atenolol; Body Weight; Cardiovascula | 2009 |
Remodeling of cardiac cholinergic innervation and control of heart rate in mice with streptozotocin-induced diabetes.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Atropine; Blood Glucose; Body Weight; Data Interpret | 2011 |
Effects of exercise and beta-blocker on blood pressure and baroreflexes in spontaneously hypertensive rats.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Baroreflex; Bisoprolol; Blood Pressure; Body Weight; | 2003 |
Intrapericardial delivery enhances cardiac effects of sotalol and atenolol.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Body Weight; Drug Delivery Systems; Infusions, Intra | 2004 |
Extract of Lycopus europaeus L. reduces cardiac signs of hyperthyroidism in rats.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Blood Pressure; Body Temperature; Body Weight; Eatin | 2006 |
Valsartan but not atenolol improves vascular pathology in diabetic Ren-2 rat retina.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically | 2007 |
Social isolation disrupts autonomic regulation of the heart and influences negative affective behaviors.
Topics: Analysis of Variance; Animals; Arrhythmia, Sinus; Arvicolinae; Atenolol; Autonomic Nervous System; B | 2007 |
Defining the chronic impacts of atenolol on embryo-larval development and reproduction in the fathead minnow (Pimephales promelas).
Topics: Animals; Atenolol; Body Weight; Cyprinidae; Embryo, Nonmammalian; Female; Male; Models, Biological; | 2008 |
The effects of beta adrenoceptor blockade with atenolol on myocardial cellular and subcellular hypertrophy in spontaneously hypertensive rats.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Blood Pressure; Body Water; Body Weight; Cardiomegal | 1983 |
The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Atenolol; Blood Pressure; Body Weight; Drug Interactions; Femal | 1984 |
Flurbiprofen interaction with single doses of atenolol and propranolol.
Topics: Adult; Aldosterone; Atenolol; Blood Pressure; Body Weight; Female; Flurbiprofen; Heart Rate; Humans; | 1984 |
[Effect of the anti-hypertensive therapy with atenolol on the dimensions and function of the left ventricle].
Topics: Adult; Atenolol; Body Weight; Echocardiography; Female; Hemodynamics; Humans; Hypertension; Male; Mi | 1982 |
beta-Adrenoreceptor blockage and genetic hypertension development in rats.
Topics: Acebutolol; Animals; Atenolol; Blood Pressure; Body Weight; Depression, Chemical; Hemodynamics; Hype | 1980 |
[Evaluation of the combination of atenolol and indapamide in the therapy of arterial hypertension (with data concerning toxicity and tolerance in the experimental animal)].
Topics: Adult; Aged; Animals; Atenolol; Blood Pressure; Body Weight; Diuretics; Dogs; Drug Therapy, Combinat | 1981 |
Enhancement of arterial relaxation by long-term atenolol treatment in spontaneously hypertensive rats.
Topics: Aging; Animals; Atenolol; Blood Pressure; Body Weight; Calcium; Endothelium, Vascular; Heart Rate; H | 1994 |
Evaluation of the tumor-promoting activity of two beta-adrenoreceptor blocking agents, propranolol and atenolol, in liver of Fischer 344 rats.
Topics: Animals; Atenolol; Body Weight; Carcinogens; Diethylnitrosamine; Female; gamma-Glutamyltransferase; | 1994 |
Carbon monoxide-induced cardiac hypertrophy is not reduced by alpha- or beta-blockade in the rat.
Topics: Animals; Atenolol; Blood Pressure; Body Weight; Carbon Monoxide; Cardiomegaly; Heart Rate; Lung; Mal | 1993 |
The role of renal dopamine in the reduction of high blood pressure by beta 1-selective beta-blocker with intrinsic sympathomimetic activity in spontaneously hypertensive rats.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Atenolol; Blood Pressu | 1995 |
Beta blockers in pregnancy and their effect on regional Doppler ultrasound and fetal weight.
Topics: Acebutolol; Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Body Weight; Female; Fet | 1996 |
Influence of beta-adrenergic antagonists on cell proliferation rates in the kidney of untreated and diethylnitrosamine-treated male F344 rats.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Body Weight; Carcinogens; Cell Division; Diethylnitr | 1999 |
Cardiac betaARK1 upregulation induced by chronic salt deprivation in rats.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; beta-Adrenergic Receptor Kinases; Blood Pressure; Bo | 2001 |
Attenuation of hypertension, cardiomyocyte hypertrophy, and myocardial fibrosis by beta-adrenoceptor blockers in rats under long-term blockade of nitric oxide synthesis.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Atenolol; Blood Pressu | 2002 |
Nitric-oxide-mediated relaxations in salt-induced hypertension: effect of chronic beta1 -selective receptor blockade.
Topics: Adrenergic beta-Antagonists; Animals; Aorta; Atenolol; Benzopyrans; Blood Pressure; Body Weight; Dru | 2002 |
Dietary Mg(2+) supplementation restores impaired vasoactive responses in isolated rat aorta induced by chronic ethanol consumption.
Topics: Animals; Aorta, Thoracic; Atenolol; Blood Pressure; Body Weight; Dietary Supplements; Dose-Response | 2002 |
Hemodynamic adjustments in hypertensive patients developing circulatory congestion during beta-adrenergic blockade.
Topics: Adult; Aged; Atenolol; Blood Pressure; Body Weight; Cardiac Output; Drug Evaluation; Female; Heart F | 1979 |
Chronic atenolol treatment and hypertension development in spontaneously hypertensive rats.
Topics: Animals; Atenolol; Blood Pressure; Body Weight; Heart; Heart Rate; Hypertension; Male; Organ Size; P | 1978 |
Behavioral and biochemical studies in rats following prenatal treatment with beta-adrenoceptor antagonists.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Animals, Newborn; Atenolol; Avoidance Le | 1991 |
Differential effects of 3 beta blockers on lipid peroxidation in hyperthyroid muscle.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Body Weight; Carteolol; Hyperthyroidism; Lipid Perox | 1990 |
T3 plus high doses of beta-blockers: effects on energy intake, body composition, bat and heart in rats.
Topics: Adipose Tissue; Adipose Tissue, Brown; Adrenergic beta-Antagonists; Animals; Atenolol; Body Composit | 1990 |
Effect of experimental diabetes mellitus on the pharmacokinetics of atenolol enantiomers in rats.
Topics: Animals; Atenolol; Blood Glucose; Body Weight; Creatinine; Diabetes Mellitus, Experimental; Male; Ra | 1991 |
Antiproteinuric effect of captopril in a patient with lupus nephritis and intractable nephrotic syndrome.
Topics: Adult; Atenolol; Body Weight; Captopril; Creatinine; Female; Furosemide; Humans; Hypertension; Lupus | 1990 |
[The clinical profile of hypertensive patients can predict the need for combining a second or third drug with atenolol in the initial treatment of light and moderate essential arterial hypertension].
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Body Weight; Diet, Sodium-Restricted | 1990 |
The effect of triple drug therapy on renal function in patients with essential hypertension.
Topics: Adrenergic beta-Antagonists; Aged; Aldosterone; Antihypertensive Agents; Atenolol; Betaxolol; Blood | 1989 |
Food intake, body and heart composition, and heart rate in T3 plus atenolol-treated rats.
Topics: Animals; Atenolol; Body Composition; Body Weight; Eating; Heart; Heart Rate; Male; Organ Size; Rats; | 1989 |
Effects of beta-adrenoceptor blocking agents on isolated atrial and papillary muscles from experimentally diabetic rats.
Topics: Animals; Atenolol; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Dose-Response Relati | 1989 |
Role of endogenous beta-adrenergic mechanism in the pathogenesis of spontaneous myocardial fibrosis in rats.
Topics: Animals; Atenolol; Body Weight; Endomyocardial Fibrosis; Female; Heart Ventricles; Male; Rats; Rats, | 1988 |
Increased plasma vasopressin in low renin essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Arginine Vasopressin; Atenolol; Blood Pressure; Body Weight; Die | 1986 |
Balance among autonomic controls of heart rate in neonatal spontaneously hypertensive and borderline hypertensive rats.
Topics: Age Factors; Animals; Animals, Newborn; Antihypertensive Agents; Atenolol; Atropine Derivatives; Aut | 1988 |
The influence of atenolol and prazosin on serum lipids and atherosclerosis in minipigs fed a hyperlipidemic diet.
Topics: Animals; Arteriosclerosis; Atenolol; Body Weight; Cholesterol, Dietary; Diet; Female; gamma-Glutamyl | 1988 |
Participation of endogenous catecholamines in the regulation of left ventricular mass in progeny of hypertensive parents.
Topics: Adolescent; Adult; Aldosterone; Atenolol; Blood Pressure; Blood Volume; Body Weight; Cardiomegaly; C | 1985 |
Effects of ephedrine and atenolol on the development of obesity and diabetes in ob/ob mice.
Topics: Aging; Animals; Atenolol; Blood Glucose; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Experime | 1986 |
[Effect of atenolol on MAO activities in SHR].
Topics: Animals; Atenolol; Body Weight; Kidney; Liver; Male; Mesenteric Arteries; Monoamine Oxidase; Myocard | 1986 |
Effect of atenolol on serum beta 2-microglobulin level in hypertensive diabetic patients.
Topics: Atenolol; beta 2-Microglobulin; Blood Glucose; Blood Urea Nitrogen; Body Weight; Creatinine; Diabete | 1985 |